In conclusion, in this study of CKD patients (stages 3~5) receiving ACEIs/ARBs who were enrolled in a pre-ESRD program with multidisciplinary teams, SGLT2 inhibitor use was associated with a notably greater incidence of GUTIs, regardless of GUTI history. Here, SLC5A2 is linked to chronic kidney disease.